Use of Endocrine Therapy for Breast Cancer Risk Reduction
Introduction
Introduction
Diagnosis
...iagnosis
...e 1. Breast Cancer Risk Assessment...
Treatment
...reatment...
...2. Summary of All Recommendations...
...oxifen
...scussed as an option to reduce the ri...
...s NOT recommended for use in women with a history...
...NOT recommended for women who are pr...
...ended in combination with hormone therapy. (EB, S...
...should include a timely work-up of abnormal...
...patients and health care providers sh...
...20 mg/d orally for 5 years. (EB, S)7251...
...evidence-based on 5 RCTs with low r...
...aloxifen...
...hould be discussed as an option to reduce the...
...longer than 5 years in women with ost...
...used for BC risk reduction in premenopausal...
...OT recommended for use in women with a hi...
...scussions with patients and health car...
...E: 60 mg/d orally for 5 years. (EB,...
...g evidence-based on 4 RCTs with low risk of bias)...
...mestane...
...sed as an alternative to tamoxifen and/or ralox...
...ld NOT be used for BC risk reductio...
...ussions with patients and health care provider...
...25 mg/d orally for 5 years. (EB, M)7251...
...rate evidence-based on 1 RCT with...
Anastrozo...
...1 mg/day orally for 5 years) should be...
...ikely to benefit are those with one of more of...
...inicians should NOT prescribe anas...
...iscussions between patients and health...
...or to initiating an aromatase inhib...
...should inform women also of the po...
...utweigh harms; Evidence quality: high; Stro...
...3. Summary of Agent IndicationsHaving...
...le 4. Adverse Effects of Endocrine TherapyHaving t...